Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-
6 hours ago
- #Clinical Trial
- #Immunotherapy
- #Ovarian Cancer
- SL-172154 is a bispecific CD47 inhibitor and CD40 agonist investigated in a Phase Ib trial with MIRV or PLD for platinum-resistant ovarian cancer.
- Most common treatment-emergent adverse events included blurred vision, nausea, and infusion reactions with MIRV; nausea, constipation, neutropenia with PLD.
- Objective response rate was 33% in FRα high subgroup with MIRV, 15% in FRα medium/low, and 20% with PLD, not improving over MIRV alone but showing potential with PLD.
- Limitations like poor tumor penetration and insufficient CD47 blockade may explain the lack of enhanced efficacy with MIRV combination.
- Study involved 86 patients across multiple countries, with ethical approvals and significant conflicts of interest among authors related to pharmaceutical funding.